1
Anemia is related to drug resistance and treatment failure in uncomplicated malaria.
2
Children with uncomplicated malaria did not have an increased frequency of cognitive deficits.
3
Artemether-lumefantrine is the most widely recommended treatment for uncomplicated malaria globally.
4
Conclusion: Pregnant women become more thrombocytopenic than non-pregnant women with acute uncomplicated malaria.
5
Background: Combination therapies are now recommended to treat uncomplicated malaria.
6
Antimalarial drug combination therapy is now being widely used for the treatment of uncomplicated malaria.
7
Sixty-one percent of the HCPs reported having ever encountered ACT failures while treating uncomplicated malaria.
8
Conclusions: AL and DP remain efficacious for the treatment of uncomplicated malaria among children in western Kenya.
9
Background: Artemether-lumefantrine (AL) was adopted as first-line treatment for uncomplicated malaria in Kenya in 2006.
10
Episodes of uncomplicated malaria were treated with artemether-lumefantrine (AL) with active follow-up for 28 days.
11
Each received mixed supervised and unsupervised artemether-lumefantrine for uncomplicated malaria, using a standard six-dose regimen, by weight.
12
None of the above polymorphisms predicted treatment failure among 66 subjects treated with quinine for uncomplicated malaria.
13
Risks of parasitological failure were determined for each episode of uncomplicated malaria and clinical parameters were followed.
14
DP thus appears to be a good alternative to AL as first-line treatment of uncomplicated malaria in Uganda.
15
One hundred three unrelated children with uncomplicated malaria from the Unguja and Pemba islands of Zanzibar were enrolled.
16
These observations may help to explain the discrepancy in some published association studies involving G6PD deficiency and uncomplicated malaria.
